Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Retrospective Real-World Study Based on RATIONALE-307
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Summary
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.
Official title: Long-Term Efficacy and Safety Analysis of First-Line Tislelizumab in Patients With Advanced Squamous NSCLC: a Retrospective Real-World Study Based on RATIONALE-307
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
109
Start Date
2026-02-28
Completion Date
2027-12-31
Last Updated
2026-03-27
Healthy Volunteers
Not specified
Interventions
No intervention
No intervention
Locations (1)
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China